Connect with us

Legal & Regulation

High-Ranking Democrat Vends “Gateway Drug Theory” to Shut Cannabis Legalization Campaign

Abby Veronika



High-Ranking Democrat Vends “Gateway Drug Theory” to Shut Cannabis Legalization Campaign
- Ad -

The second-highest-ranking Democrat in the U.S. House of Representatives wrote on Monday that he remains sagacious of supporting the legalization of marijuana because he believes it is a gateway to “harder, very harmful drugs.”

Majority Leader Steny Hoyer (D-MD) wrote in a constituent letter obtained by Marijuana Moment that he initially supported the legalization of medical marijuana and voted in favor of an amendment to protect medical marijuana legal states from federal interference. However, he is offering a counter-argument for the legalization in 2019 and thinks that marijuana is a threshold drug that leads to the use of other harmful drugs.

There are researches to invalidate the gateway theory. The vast majority of people use this illicit substance and would therefore logically be one of the first drugs that a person uses in many cases. Also, the same logic could be used to certify that any extensively used drug like nicotine or alcohol leads people to use substances like heroin or cocaine.

In fact, a growing body of research has demonstrated that for some users, cannabis provides an off-ramp or alternative to addictive prescription medications and illicit drugs.

Erik Altieri, executive director of NORML (National Organization for the Reform of Marijuana Laws) told Marijuana Moment that Marijuana legalization and regulation have been proven and leads to a decrease in usage among the youth and helps people who are struggling with opioid addiction.

“By sticking to the long-debunked myth of marijuana as a gateway drug, Hoyer is denying actual science and failing his constituents by advancing talking points straight from the Reefer Madness era,”

Altieri added.

After this story was originally published in Marijuana Moment, Mckayla Wilkes, who is contesting against Hoyer in a primary challenge for his congressional seat, criticized the requisite in a tweet in which she stated her support for legalizing cannabis and expunging past convictions. 

Robert Capecchi, the constituent who wrote to Hoyer about legalization told that it is incredibly disappointing to see anti Cannabis policy reform based on the debunked ‘gate-way theory,’ especially from one of the most senior members of Democratic Leadership.

 “This is not about use; people use and will continue to use cannabis regardless of federal law, It’s about safety, it’s about equity, it’s about compassion, and it’s about responsible regulation and accurate education,”

said Capecchi.

At a time when innumerable cannabis legalization bills are being proposed and a majority of Democrats are verbally supporting broad reform, it’s preposterous for a party leader to openly peddle what is considered an outdated and inaccurate theory. 

Abby Veronika is one of the leading researchers here and resides in Southern California where she is a student at a local college to study Communications. While she is a best-selling women’s romance novel author on Amazon, her real expertise and passion lives within the cannabis, health and nutrition space.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.